133 related articles for article (PubMed ID: 9435864)
21. Idiotype vaccination strategies against a murine B-cell lymphoma: dendritic cells loaded with idiotype and bispecific idiotype x anti-class II antibodies can protect against tumor growth.
Bohlen H; Thielemanns K; Tesch H; Engert A; Wolf HJ; van Camp B; Urbain J; Diehl V
Cytokines Mol Ther; 1996 Dec; 2(4):231-8. PubMed ID: 9384709
[TBL] [Abstract][Full Text] [Related]
22. Lysis of murine B lymphoma cells by transgenic phagocytes via a human Fc gamma RI x murine MHC class II bispecific antibody.
Heijnen IA; Glennie MJ; van de Winkel JG
Cancer Immunol Immunother; 1997; 45(3-4):166-70. PubMed ID: 9435865
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic efficacy of FcgammaRI/CD64-directed bispecific antibodies in B-cell lymphoma.
Honeychurch J; Tutt AL; Valerius T; Heijnen IA; Van De Winkel JG; Glennie MJ
Blood; 2000 Nov; 96(10):3544-52. PubMed ID: 11071653
[TBL] [Abstract][Full Text] [Related]
24. Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells.
Kipriyanov SM; Moldenhauer G; Strauss G; Little M
Int J Cancer; 1998 Aug; 77(5):763-72. PubMed ID: 9688311
[TBL] [Abstract][Full Text] [Related]
25. Treatment of mice bearing BCL1 lymphoma with bispecific antibodies.
Brissinck J; Demanet C; Moser M; Leo O; Thielemans K
J Immunol; 1991 Dec; 147(11):4019-26. PubMed ID: 1940384
[TBL] [Abstract][Full Text] [Related]
26. CD3 x CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin's lymphoma.
Manzke O; Titzer S; Tesch H; Diehl V; Bohlen H
Cancer Immunol Immunother; 1997; 45(3-4):198-202. PubMed ID: 9435873
[TBL] [Abstract][Full Text] [Related]
27. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct.
Dreier T; Baeuerle PA; Fichtner I; Grün M; Schlereth B; Lorenczewski G; Kufer P; Lutterbüse R; Riethmüller G; Gjorstrup P; Bargou RC
J Immunol; 2003 Apr; 170(8):4397-402. PubMed ID: 12682277
[TBL] [Abstract][Full Text] [Related]
28. A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells.
Guettinger Y; Barbin K; Peipp M; Bruenke J; Dechant M; Horner H; Thierschmidt D; Valerius T; Repp R; Fey GH; Stockmeyer B
J Immunol; 2010 Feb; 184(3):1210-7. PubMed ID: 20042573
[TBL] [Abstract][Full Text] [Related]
29. Tumor-specific targeting of T helper type 1 (Th1) cells by anti-CD3 x anti-c-ErbB-2 bispecific antibody.
Ohmi Y; Shiku H; Nishimura T
Cancer Immunol Immunother; 1999 Nov; 48(8):456-62. PubMed ID: 10550550
[TBL] [Abstract][Full Text] [Related]
30. T cell activation and retargeting using staphylococcal enterotoxin B and bispecific antibody: an effective in vivo antitumor strategy.
Porter LE; Nelson H; Ethem Gecim I; Rice DC; Thibault C; Chapoval AI
Cancer Immunol Immunother; 1997; 45(3-4):180-3. PubMed ID: 9435868
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy of B-cell non-Hodgkin lymphoma by targeting the chemokine receptor CXCR5 in a preclinical mouse model.
Panjideh H; Müller G; Koch M; Wilde F; Scheu S; Moldenhauer G; Lipp M
Int J Cancer; 2014 Dec; 135(11):2623-32. PubMed ID: 24729415
[TBL] [Abstract][Full Text] [Related]
32. Activation and preferential expansion of rat cytotoxic (CD8) T cells in vitro and in vivo with a bispecific (anti-TCR alpha/beta x anti-CD2) F(ab')2 antibody.
Tutt AL; Reid R; Wilkins BS; Glennie MJ
J Immunol; 1995 Sep; 155(6):2960-71. PubMed ID: 7673714
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy of B-cell lymphoma with CD3x19 bispecific antibodies: costimulation via CD28 prevents "veto" apoptosis of antibody-targeted cytotoxic T cells.
Daniel PT; Kroidl A; Kopp J; Sturm I; Moldenhauer G; Dörken B; Pezzutto A
Blood; 1998 Dec; 92(12):4750-7. PubMed ID: 9845541
[TBL] [Abstract][Full Text] [Related]
34. Approaches to lung cancer treatment using the CD3 x EGP-2-directed bispecific monoclonal antibody BIS-1.
Kroesen BJ; Nieken J; Sleijfer DT; Molema G; de Vries EG; Groen HJ; Helfrich W; The TH; Mulder NH; de Leij L
Cancer Immunol Immunother; 1997; 45(3-4):203-6. PubMed ID: 9435874
[TBL] [Abstract][Full Text] [Related]
35. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.
Weiner GJ; Kostelny SA; Hillstrom JR; Cole MS; Link BK; Wang SL; Tso JY
J Immunol; 1994 Mar; 152(5):2385-92. PubMed ID: 8133049
[TBL] [Abstract][Full Text] [Related]
36. A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
Robinson HR; Qi J; Cook EM; Nichols C; Dadashian EL; Underbayev C; Herman SEM; Saba NS; Keyvanfar K; Sun C; Ahn IE; Baskar S; Rader C; Wiestner A
Blood; 2018 Aug; 132(5):521-532. PubMed ID: 29743179
[TBL] [Abstract][Full Text] [Related]
37. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3).
Demanet C; Brissinck J; Van Mechelen M; Leo O; Thielemans K
J Immunol; 1991 Aug; 147(3):1091-7. PubMed ID: 1830596
[TBL] [Abstract][Full Text] [Related]
38. Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan.
Zhang X; Yang Y; Zhang L; Lu Y; Zhang Q; Fan D; Zhang Y; Zhang Y; Ye Z; Xiong D
J Hematol Oncol; 2017 Feb; 10(1):56. PubMed ID: 28228105
[TBL] [Abstract][Full Text] [Related]
39. Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. I. Clinical phase I evaluation.
Manzke O; Tesch H; Borchmann P; Wolf J; Lackner K; Gossmann A; Diehl V; Bohlen H
Int J Cancer; 2001 Feb; 91(4):508-15. PubMed ID: 11251974
[TBL] [Abstract][Full Text] [Related]
40. Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells.
Cochlovius B; Kipriyanov SM; Stassar MJ; Christ O; Schuhmacher J; Strauss G; Moldenhauer G; Little M
J Immunol; 2000 Jul; 165(2):888-95. PubMed ID: 10878363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
